Advances in the treatment of soft tissue sarcoma: focus on eribulin.

about

Advances in the treatment of soft tissue sarcoma: focus on eribulin.

Item

http://www.wikidata.org/entity/Q49261685

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Advances in the treatment of soft tissue sarcoma: focus on eribulin.

@en

Advances in the treatment of soft tissue sarcoma: focus on eribulin.

@nl

type

Item

label

Advances in the treatment of soft tissue sarcoma: focus on eribulin.

@en

Advances in the treatment of soft tissue sarcoma: focus on eribulin.

@nl

prefLabel

Advances in the treatment of soft tissue sarcoma: focus on eribulin.

@en

Advances in the treatment of soft tissue sarcoma: focus on eribulin.

@nl

P1476

Advances in the treatment of soft tissue sarcoma: focus on eribulin

@en

P2093

Khin Thway

http://www.w3.org/2001/XMLSchema#string

Maria Theochari

http://www.w3.org/2001/XMLSchema#string

Panagiotis Koliou

http://www.w3.org/2001/XMLSchema#string

Seth M Pollack

http://www.w3.org/2001/XMLSchema#string

P2860

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma

Principles in Management of Soft Tissue Sarcoma

Eribulin in Cancer Treatment

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Smad4 is essential for down-regulation of E-cadherin induced by TGF-beta in pancreatic cancer cell line PANC-1

Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Redefining the target: chemotherapeutics as antiangiogenics.

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states

P304

207-216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S143019

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vasilis Karavasilis

Robin L Jones

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29440930

http://www.w3.org/2001/XMLSchema#string

P932

5798537

http://www.w3.org/2001/XMLSchema#string